

Resource Summary Report

Generated by [dkNET](#) on Aug 16, 2026

pBABE-puro

RRID:Addgene_1764

Type: Plasmid

Proper Citation

RRID:Addgene_1764

Plasmid Information

URL: <http://www.addgene.org/1764>

Proper Citation: RRID:Addgene_1764

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:2194165](#)

Vector Backbone Description: Backbone Size:5169; Vector Backbone:pBABE-puro; Vector Types:Mammalian Expression, Retroviral; Bacterial Resistance:Ampicillin

Comments: Please acknowledge Jay Morgenstern and Hartmut Land and cite the following article if you use this plasmid in a publication: Morgenstern JP, Land H., 1990, Nucleic Acids Research 18(12):3587-96. If you are using the pBABE protocol from the Weinberg Lab to generate virus, please note that the Weinberg Lab recommends using pUMVC (Addgene #8449) and VSV-G (#8454) for packaging. The pCL-Eco plasmid listed in their protocol should be substituted with pUMVC.

Plasmid Name: pBABE-puro

Record Creation Time: 20220422T222019+0000

Record Last Update: 20260815T081058+0000

Ratings and Alerts

No rating or validation information has been found for pBABE-puro.

No alerts have been found for pBABE-puro.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 304 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Wessendorf-Rodriguez K, et al. (2026) Modeling lipid homeostasis using stable isotope tracing and flux analysis. *Cell metabolism*, 38(3), 460.

Kim YM, et al. (2026) Targeting eIF4A-dependent translation in genetically complex sarcoma. *JCI insight*, 11(10).

Powers J, et al. (2026) eIF4G2-dependent translation restrains pancreatic cancer progression. *bioRxiv : the preprint server for biology*.

Chen Y, et al. (2026) Canagliflozin and Brusatol Synergize against LKB1-KEAP1 Co-Mutant NSCLC through AKT Suppression. *International journal of biological sciences*, 22(9), 4618.

Lu G, et al. (2026) In vivo detection of immune responses via cytokine activity labeling. *Cell*.

Nam JS, et al. (2025) An Iron-regulated Signalling Pathway Controls Adipose Browning and Cancer Cachexia. *bioRxiv : the preprint server for biology*.

García-Castillo J, et al. (2025) MicroRNA 196a contributes to the aggressiveness of esophageal adenocarcinoma through the MYC/TERT/NF κ B axis. *Molecular oncology*, 19(11), 3305.

Thoenen E, et al. (2025) Suppression of stress granule formation is a vulnerability imposed by mutant p53. *Nature communications*, 16(1), 2365.

Foote JB, et al. (2025) A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer. *Cancer research*, 85(5), 956.

Yang HJ, et al. (2025) ACTL6A depletion induces KLF4-mediated anti-tumorigenic effects in colorectal cancer. *Cell death & disease*, 16(1), 653.

Oles AR, et al. (2025) MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD. *iScience*, 28(8), 113149.

Liang X, et al. (2025) Limited activation interdependence and differing patterns of the in vivo effects of IKK1 and IKK2 downstream of NIK. *Cell reports*, 44(10), 116404.

Ramakrishnan G, et al. (2025) Deletion of AMP-activated protein kinase impairs metastasis and is rescued by ROS scavenging or ectopic CD36 expression. *Cell reports*, 44(1), 115183.

Matsuura H, et al. (2025) High Antigenicity for Treg Cells Confers Resistance to PD-1 Blockade Therapy via High PD-1 Expression in Treg Cells. *Cancer science*, 116(5), 1214.

Prevost CT, et al. (2025) NRF2 regulates lipid droplet dynamics to prevent lipotoxicity. *iScience*, 28(7), 112925.

Malvi P, et al. (2025) PDE7A inhibition suppresses triple-negative breast cancer by attenuating de novo pyrimidine biosynthesis. *Cell reports. Medicine*, 6(9), 102356.

Chourasia S, et al. (2025) MTCH2 controls energy demand and expenditure to fuel anabolism during adipogenesis. *The EMBO journal*, 44(4), 1007.

Sad K, et al. (2025) Histone H3E50K remodels chromatin to confer oncogenic activity and support an EMT phenotype. *NAR cancer*, 7(1), zcaf002.

Jiang L, et al. (2025) Seryl-tRNA synthetase inhibits Wnt signaling and breast cancer progression and metastasis. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(1), e70294.

Roets LE, et al. (2025) The cancer-associated SF3B1K700E spliceosome mutation confers enhanced sensitivity to BV-6-induced cytotoxicity. *Cell death & disease*, 16(1), 476.